Skip To Main Content
Turna Ray on Muck Rack

Turna Ray

Verified
New York
As seen in: 360Dx, GenomeWeb, Precision Oncology News, The World from PRX, Crain's Chicago Business, Science Friday, Modern Healthcare, Precision Medicine Online
Journalist: Personalized medicine, genomics, cancer @GenomeWeb genomeweb.com Managing editor: Precision Medicine Online precisionmedicineonline.com
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Turna

Contact Turna, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

H1 Precision Medicine Approvals on Par With Last Year, Despite Funding and Regulatory Uncertainty

|
By Turna Ray Verified
| Precision Medicine Online Verified
NEW YORK – At the half-year mark, the US Food and Drug Administration has approved 17 precision medicine drugs, on par with the number it greenlit in the same period last year. During the first six months of 2026, the agency expanded 14 treatments into new indications and approved three new molecular entities. By this time in 2025, the FDA had approved seven NMEs, expanded nine indications, and amended one indication.
Open in Who Shared Issue with article?

Genetic Testing Challenges in Precision Medicine: HFE Carriers Misdiagnosed With Hemochromatosis

|
By Turna Ray Verified
| Precision Medicine Online Verified
Precision Medicine Online and My Gene Counsel have partnered since 2019 on the "Genetic Testing Challenges" series to highlight real-world issues medical professionals are encountering as genetic tests are increasingly used in patient care.
Open in Who Shared Issue with article?

ASCO Won't Recommend Galleri as NHS Trial Data Reignites Debate Over MCED Evidence Standards

|
By Kelsy Ketchum Verified, Turna Ray Verified
| GenomeWeb Verified
CHICAGO – The American Society of Clinical Oncology will not recommend Grail's Galleri test for detecting cancers early after seeing data from a large, prospective randomized-controlled trial.
Open in Who Shared View Duplicates (2) Issue with article?
See all 440 articles